Omeprazolo Fg (Omeprazole)

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease (PUD): supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSAID‑associated ulcer prevention: lowers risk of ulcer formation in patients requiring long‑term NSAID therapy.

• Omeprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid production, it markedly reduces both basal and stimulated gastric acidity, allowing mucosal healing and symptom relief.

Adverse reactions to omeprazole are generally dose‑dependent and may vary in frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or vomiting: transient gastrointestinal upset.
• Abdominal pain or flatulence: mild discomfort.
• Constipation: occasional bowel habit change.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis risk.
• Acute interstitial nephritis: renal inflammation.
• Hypomagnesemia: low serum magnesium levels.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Liver enzyme elevation: potential hepatotoxicity.
• Fracture risk: possible reduction in bone mineral density with long‑term use.

When prescribing omeprazole, clinicians should consider several safety aspects.

• Assess renal and hepatic function: dose adjustment may be required in impairment.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term users: evaluate need for continued therapy after 8‑12 weeks.
• Pregnancy and lactation: use only if clearly indicated after risk‑benefit assessment.
• Elderly patients: start with the lowest effective dose and monitor for adverse effects.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir or other protease inhibitors: decreased absorption, loss of antiviral efficacy.
• Warfarin: enhanced anticoagulant effect, monitor INR closely.

Moderate Interactions (Monitor Closely)

• Methotrexate: increased serum levels, risk of toxicity.
• Digoxin: higher plasma concentrations, monitor cardiac status.
• Diazepam: elevated levels may cause sedation, adjust dose if needed.
• Iron supplements: reduced absorption, separate dosing by at least 2 hours.